LD
Therapeutic Areas
Neuphoria Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 3 (planning) |
| Next-Gen α7 NAM Program | CNS Disorders | Discovery/Preclinical |
| MK-1167 (via Merck) | Cognitive Dysfunction (Alzheimer's, Schizophrenia) | Phase 2 (imminent) |
| BNC101 (via Carina Biotech) | Solid Tumors | Out-licensed |
Leadership Team at Neuphoria Therapeutics
SP
Spyros Papapetropoulos
President & CEO, Executive Director
TC
Tim Cunningham
Chief Financial Officer
AF
Alan Fisher
Non-Executive Chairman
DW
David Wilson
Non-Executive Director
JR
Jane Ryan
Non-Executive Director
MD
Miles Davies
Non-Executive Director